Per the National Cancer Institute, colorectal cancer is the second leading cause of death in the U.S. Per the World Health Organization, colorectal cancer is a major cause of morbidity and mortality and the fourth most common form of cancer worldwide. Almost half of colorectal tumors are located in the rectum. According to the American Society of Colon and Rectal Surgeons, about half of all patients with colorectal cancer will develop metastatic disease at some point, and in most cases this disease will be fatal.The study is open for patient enrollment. The following research institutions will initially participate in the study: Universitätsklinikum Erlangen (Principal Investigator: Associate Professor Oliver Ott, MD, email@example.com), Universitätsklinikum Munich Grosshadern (Associate Professor Lars Lindner, MD) and UMS Tübingen (Professor Daniel Zips, MD). These sites all utilize the BSD-2000 Hyperthermia System. About the BSD-2000 Hyperthermia System The BSD-2000 – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The BSD-2000 also has CE (Conformité Européenne) Marking approval for the commercial sale in Europe. CE Marking approval is also recognized in many countries outside of the EU. About BSD Medical Corporation BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for many years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com. Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.